A lead analyst at AMR highlighted that the metabolomics market in Asia-Pacific is anticipated to grow at the fastest CAGR during the forecast period.
Allied Market Research published a research
report on the metabolomics market. The findings of
the report states that the global market for metabolomics generated $2.03 billion
in 2020, and is projected to reach $6.66 billion by 2030, registering a CAGR of
12.2% from 2021 to 2030. The report offers valuable information on changing
market dynamics, major segments, top investment pockets, and competitive
scenario for market players, investors, shareholders, and new entrants.
The report provides detailed insights on
drivers, restrains, and opportunities to help the market players in devising
several growth strategies. Surge in the adoption of metabolomics in precision
medicine, increase in the cases of chronic diseases, introduction of diagnostics
tests for diagnosis of chronic diseases, and rise in the launches of innovative
drugs from prominent manufacturers are expected to drive the growth of the
global metabolomics market. On the other hand, adverse issues concerning data
examination and processing is expected to hinder the growth to some extent.
However, increase in R&D expenditure and technological advancements are
expected to create ample opportunities for the industry.
“Growth in R&D expenditure in the
pharmaceutical & biopharmaceutical industry, availability of government
& private funding for metabolomics research, and ongoing innovations in
metabolomics instruments drive the growth of the global metabolomics industry,”
said Onkar Sumant, Manager, Healthcare at Allied Market Research.
The report provides a detailed scenario of the
impact of the Covid-19 pandemic on metabolomics market globally. The outbreak
of COVID-19 has had a positive impact on the growth of the global metabolomics
market, owing to the increased use of metabolomics in research for understanding
the spread of the COVID-19 infection. In addition, it was increasingly used to
determine the effectivity of various drugs on the COVID-19 virus. Hence, this
led to abrupt surge in the use of metabolomics in COVID-19 related research,
which further led to the positive impact on the metabolomics market.
The report offers a detailed segmentation on
the global metabolomics market based on product and service, application, indication
and region.
Based on product & services, the
metabolomics bioinformatics tools and services segment held the largest market
share in 2020, holding nearly three-fourths of the global market. In addition,
the same segment is expected to cite the fastest CAGR of 12.7% during the
forecast period. The report also analyses other segment such as metabolomics instruments.
Based on application, the biomarker discovery
segment held the majority market share in 2020, holding more than two-fifths of
the global market. The personalized medicine segment, on the other hand, is
expected to cite the fastest CAGR of 15.6% during the forecast period.
Based on region, North America held the
dominating market share in 2020, holding more than two-fifths of the global
market. The Asia-Pacific region, on the other hand, is expected to cite the
fastest CAGR of 13.9% during the forecast period. The report also analyses
other regions such as Europe and LAMEA.
The key players analzyed in the global metabolomics market report include Danaher Corporation, Human Metabolome Technologies INC., LECO Corporation, Metabolon INC., Agilent Technologies INC., BiocratesLife Science AG, Bio-Rad Laboratories INC., Bruker corporation, Shimadzu Corporation, Water Corporation.
0 Comments